Skip to main content

Latest collections open to submissions

NEW: Cancer control in low- and middle-income countries

Guest Edited by Lisa A. Newman, Cristina Stefan and Shenglan Tang

Advances in personalized radiotherapy

Guest Edited by Venkata SK. Manem and Farzad Taghizadeh-Hesary

Cancer metabolism

Guest edited by Elavarasan Subramani and Marija Trajkovic-Arsic

Editors' Picks

New Content ItemEta polycaprolactone (ε-PCL) implants appear to cause a partial differentiation of breast cancer lung metastasis in a murine model

New Content ItemATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors

New Content ItemAnalysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels

Trending BMC Cancer Articles

Click here to view which Articles have been shared most in the last month!


Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions

Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions

Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020

Cross journal collection: Precision Oncology
Collection published: 28 August 2019

Browse all BMC Cancer collection contributions

Aims and Scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here

May - Melanoma Awareness Month

July - Sarcoma Awareness Month

On the occasion of the Melanoma Awareness Month we hope you will enjoy reading the research article published in BMC Cancer in 2023 suggesting that serum N-glycans can be used as biomarkers of response to ICIs, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.

New Content ItemTotal serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Become an Editorial Board Member

We are recruiting new Editorial Board Members.

Read More

New Content Item (1)

BMC Cancer is celebrating its 20th anniversary! 

Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades. 

Latest Tweets

Your browser needs to have JavaScript enabled to view this timeline

Annual Journal Metrics

  • Citation Impact
    4.638 - 2-year Impact Factor (2021)
    4.672 - 5-year Impact Factor (2021)
    1.308 - SNIP (Source Normalized Impact per Paper)
    1.134 - SJR SCImago Journal Rank (SJR)

    39 days to first decision for all manuscripts (Median)
    56 days to first decision for reviewed manuscripts only (Median)

    7,665,706 Downloads (2022)
    4,517 Altmetric mentions (2021)

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal